Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAN-RSV: Abrysvo Vaccine Effectiveness in Adults
NCT06684743Phase 4Active, not recruiting
- Start
- Nov 2024
- Primary completion
- May 2028
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
A Phase 4 trial of RSVpreF vaccine in respiratory syncytial virus infection (RSV). Started Nov 2024; status: active, not recruiting.
02
Drugs
RSVpreF vaccine
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT06684743.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06684743.